Monday Lunch Live

16th October 2023

A Research Statement from the American Society of Clinical Oncology (ASCO), released 2 October 2023 has outlined new recommendations for appropriate assessment of ovarian toxicity in cancer clinical trials.

Previously, there has been inadequate data regarding whether newer cancer treatments can cause treatment-related infertility and early-onset menopause, despite the importance of this information to young women.

This statement calls for ovarian toxicity monitoring to be standard in cancer clinical trials involving premenopausal patients and outlines the optimal way to do this – including ovarian function tests at trial outset and 12 to 24 months after women stop taking the trial drug. As a result, young women who enrol in clinical trials can be more comprehensively monitored to check if new treatments have any impact on their ovaries.

In this webinar, Dr Wanda Cui discusses the recommendations and what clinicians should be aware of.